Tempus AI, Inc. (TEM)

NASDAQ: TEM · Real-Time Price · USD
59.00
+7.65 (14.90%)
At close: Mar 24, 2025, 4:00 PM
59.35
+0.35 (0.59%)
After-hours: Mar 24, 2025, 7:59 PM EST
14.90%
Market Cap 10.16B
Revenue (ttm) 693.40M
Net Income (ttm) -746.33M
Shares Out 172.21M
EPS (ttm) -6.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 12,729,467
Open 54.93
Previous Close 51.35
Day's Range 54.18 - 59.21
52-Week Range 22.89 - 91.45
Beta n/a
Analysts Buy
Price Target 61.22 (+3.76%)
Earnings Date May 17, 2025

About TEM

Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharma... [Read more]

Sector Healthcare
IPO Date Jun 14, 2024
Employees 2,400
Stock Exchange NASDAQ
Ticker Symbol TEM
Full Company Profile

Financial Performance

In 2024, Tempus AI's revenue was $693.40 million, an increase of 30.38% compared to the previous year's $531.82 million. Losses were -$746.33 million, 180.6% more than in 2023.

Financial numbers in USD Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for TEM stock is "Buy." The 12-month stock price forecast is $61.22, which is an increase of 3.76% from the latest price.

Price Target
$61.22
(3.76% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Tempus AI: The Investment Opportunity Of A Decade, Strong Buy

Tempus AI's financials have significantly improved, with positive cash flow expected next quarter and strong revenue growth projected for FY25. Q4FY24 saw record revenues, driven by a 35.8% YoY growth...

6 days ago - Seeking Alpha

Tempus Announces Acquisition of Deep 6 AI

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has acquired Deep 6 AI, a le...

13 days ago - Business Wire

Tempus AI: Buying The Dip After 2025 Guidance Raise

Tempus AI's Q4 financials were slightly below expectations but aligned with preliminary results, presenting a buying opportunity due to raised 2025 revenue guidance. The company, a leader in healthcar...

26 days ago - Seeking Alpha

Tempus AI Earnings: A Promising Business, But There Are Risks

Tempus AI's core business growth is slowing, raising doubts about its AI-led narrative and long-term sustainable growth rates. Despite impressive revenue growth projections, Tempus AI remains free cas...

27 days ago - Seeking Alpha

Tempus AI, Inc. (TEM) Q4 2024 Earnings Call Transcript

Tempus AI, Inc. (NASDAQ:TEM) Q4 2024 Earnings Conference Call February 24, 2025 4:30 PM ET Company Participants Liz Krutoholow - Investor Relations Eric Lefkofsky - Founder & Chief Executive Officer ...

4 weeks ago - Seeking Alpha

Tempus Reports Fourth Quarter and Full Year 2024 Results

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarte...

4 weeks ago - Business Wire

Tempus AI Gears Up For Q4 Earnings After 101% YTD Surge

Tempus AI Inc TEM will be reporting its fourth-quarter earnings on Monday. Wall Street expects a loss of 20 cents per share and $203.12 million in revenues as the company reports after market hours.

4 weeks ago - Benzinga

3 Biotech/Healthcare Names Under $10 I Am Buying Now

Today, I am highlighting three biotech/healthcare stocks that currently trade under $10 a share after some recent weakness. ! am slowly accumulating each of these names on these dips both straight equ...

Other symbols: ARDXGERNMRNAPSNL
4 weeks ago - Seeking Alpha

Tempus to Present at TD Cowen's 45th Annual Health Care Conference

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will present at the TD Cowen 45th Annual Health...

4 weeks ago - Business Wire

Ares Management Upsizes Tempus Debt Facilities to $560 Million

NEW YORK--(BUSINESS WIRE)--Ares Management Corporation (NYSE: ARES) (“Ares”), a leading global alternative investment manager, announced today that Ares Credit funds served as the administrative agent...

Other symbols: ARES
4 weeks ago - Business Wire

Tempus AI Is A Buy On Dips In The AI-Driven Healthcare Sector

TEM basically mixes genomic and clinical data with AI. This is at the core of their new offerings for precision diagnostics and personalized treatments. Recently, they've made some interesting moves l...

4 weeks ago - Seeking Alpha

Tempus to Participate in the Morgan Stanley Technology, Media and Telecom Conference

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the Morgan Stanley Technolo...

4 weeks ago - Business Wire

Tempus Announces Collaboration with IFLI Aimed at Supporting Development of Targeted Therapies for Follicular Lymphoma

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a new collaboration with the In...

5 weeks ago - Business Wire

Tempus to Report Fourth Quarter and Full Year 2024 Financial Results on February 24

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the fourth quarter and full ...

5 weeks ago - Business Wire

Tempus AI: In Vogue, But Better To Wait For Some Retracement

Tempus AI (TEM) has delivered an 82% YTD return, outperforming the broader market and AI-themed stocks amidst market volatility. A couple of days back, TEM closed the acquisition of Ambry Genetics whi...

6 weeks ago - Seeking Alpha

Tempus AI stock price is not cheap: is it a good buy?

Tempus AI stock price has rebounded this year as demand for artificial intelligence solutions jumped sharply. The TEM stock also jumped to $61 after the company completed its acquisition of Ambry Gene...

7 weeks ago - Invezz

Tempus Completes Acquisition of Ambry Genetics

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has completed its acquisitio...

7 weeks ago - Business Wire

Genialis Advances Biomarker Discovery to Reduce Risk in Cancer Drug Development Targeting DNA Damage Response Pathways

BOSTON--(BUSINESS WIRE)-- #ISO27001--Genialis and Debiopharm expand collaboration to develop RNA-based predictive biomarkers for DDR therapies, advancing precision oncology.

7 weeks ago - Business Wire

Tempus AI: Bringing The Promise Of AI To Healthcare

Tempus AI product lines work in concert with one another, creating a pinwheel effect as they generate data, making it more valuable over time. The company launched its 'AI-enabled personal health conc...

7 weeks ago - Seeking Alpha

What's Happening With Tempus AI (TEM) Stock?

Tempus AI (NASDAQ: TEM), a healthcare technology company, saw its stock surge 45% in a week after the company announced the launch of its AI app – Olivia. TEM stock was listed on June 14, 2024, and it...

2 months ago - Forbes

Tempus AI: Wait For A Cooldown

Tempus AI is a high-risk Buy due to its leading AI-enabled diagnostic platform, despite challenges in US healthcare reimbursement. The company connects with 2,500+ institutions to collect real-time cl...

2 months ago - Seeking Alpha

Tempus AI's Flywheel Effect: Monetizing Data In Precision Medicine

Tempus AI's scalable data ecosystem and path to profitability, with a clear trajectory to $1 billion in annual revenue, make it a compelling investment. The recent acquisition of Ambry, strategic fit,...

2 months ago - Seeking Alpha

Here's Why This Medical AI Stock Soared 35% on Tuesday

Tempus AI (TEM) stock had its best day on record on Tuesday after the medical tech company launched an AI-powered health concierge and former House Speaker Nancy Pelosi revealed she's bet on the stock...

2 months ago - Investopedia

Tempus AI Has A High Probability Of Profitability In 2025

Tempus AI, Inc. is projected to achieve 30% YoY top line growth in Q4 2024 as presented in management's preliminary results. Growth is forecast to continue in the 23-25% range in eFY25. Tempus is expe...

2 months ago - Seeking Alpha

This Medical AI Stock Is Up 30% After Launch of Personal Health App

Tempus AI says the app, olivia, is designed to centralize patients' health data and make it accessible through artificial intelligence.

2 months ago - Barrons